Aug. 8, 2023 - DelNova Inc., is developing a rescue drug, ReViVox®, to resolve side effects that may result from botulinum neurotoxin treatment. Neurotoxins, such as Botox®, Dysport®, Xeomin®, Jeauveau® and, most recently, Daxxify®, are used for wrinkle reduction in facial aesthetics....
June 1, 2022 – Mary Gardner has dedicated her entire career to the areas of innovation and commercialization for the pharma, biotech, and life science industries with positions across process design, technology, engineering, and project management…...
May 3, 2022 – What are the complications associated with Botulinum Neurotoxin therapies? Neurotoxins are administered by medical professionals and sold in the US under the brand names Botox®, Dysport®, Xeomin® and most recently Jeaveau®. These are all important and relevant questions…...
DelNova announces advances in the development of the First ever product to reverse complications arising from botulinum toxins, such as BOTOX®, Dysport®, XEOMIN®, and Jeuveau®, US patent and launch of STARTENGINE equity crowdfunding....
Steve Yoelin, M.D. is a board-certified ophthalmologist based in Orange County, CA, with approximately 20 years of experience in minimally invasive medical aesthetics, such as dermal fillers, neurotoxins, and fat reduction....
DelNova’s patent portfolio covers key markets worldwide....
